These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 29168581)

  • 1. Dopamine oxidation mediates a time-dependent pathological cascade in Parkinson's disease.
    Kulikovskaja L; Seibler P
    Mov Disord; 2018 Feb; 33(2):250. PubMed ID: 29168581
    [No Abstract]   [Full Text] [Related]  

  • 2. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease.
    Burbulla LF; Song P; Mazzulli JR; Zampese E; Wong YC; Jeon S; Santos DP; Blanz J; Obermaier CD; Strojny C; Savas JN; Kiskinis E; Zhuang X; Krüger R; Surmeier DJ; Krainc D
    Science; 2017 Sep; 357(6357):1255-1261. PubMed ID: 28882997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective and toxic roles of dopamine in Parkinson's disease.
    Segura-Aguilar J; Paris I; Muñoz P; Ferrari E; Zecca L; Zucca FA
    J Neurochem; 2014 Jun; 129(6):898-915. PubMed ID: 24548101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?
    Bisaglia M; Filograna R; Beltramini M; Bubacco L
    Ageing Res Rev; 2014 Jan; 13():107-14. PubMed ID: 24389159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: Implications in dopamine cytotoxicity and pathogenesis of Parkinson's disease.
    Jana S; Sinha M; Chanda D; Roy T; Banerjee K; Munshi S; Patro BS; Chakrabarti S
    Biochim Biophys Acta; 2011 Jun; 1812(6):663-73. PubMed ID: 21377526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysosomes to combat Parkinson's disease.
    Isacson O
    Nat Neurosci; 2015 Jun; 18(6):792-3. PubMed ID: 26007211
    [No Abstract]   [Full Text] [Related]  

  • 7. Oxidative metabolites of 5-S-cysteinyldopamine inhibit the alpha-ketoglutarate dehydrogenase complex: possible relevance to the pathogenesis of Parkinson's disease.
    Shen XM; Li H; Dryhurst G
    J Neural Transm (Vienna); 2000; 107(8-9):959-78. PubMed ID: 11041275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of pathogenesis of Parkinson's disease.
    Shadrina MI; Slominsky PA; Limborska SA
    Int Rev Cell Mol Biol; 2010; 281():229-66. PubMed ID: 20460187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological gambling in Parkinson's disease: what are the risk factors and what is the role of impulsivity?
    Heiden P; Heinz A; Romanczuk-Seiferth N
    Eur J Neurosci; 2017 Jan; 45(1):67-72. PubMed ID: 27623191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What has been learnt from study of dopamine receptors in Parkinson's disease?
    Hurley MJ; Jenner P
    Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive dopamine and hypocretin deficiencies in Parkinson's disease: is there an impact on sleep and wakefulness?
    Wienecke M; Werth E; Poryazova R; Baumann-Vogel H; Bassetti CL; Weller M; Waldvogel D; Storch A; Baumann CR
    J Sleep Res; 2012 Dec; 21(6):710-7. PubMed ID: 22747735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease.
    Haddad D; Nakamura K
    FEBS Lett; 2015 Dec; 589(24 Pt A):3702-13. PubMed ID: 26526613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's disease as a result of aging.
    Rodriguez M; Rodriguez-Sabate C; Morales I; Sanchez A; Sabate M
    Aging Cell; 2015 Jun; 14(3):293-308. PubMed ID: 25677794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine but not 3,4-dihydroxy phenylacetic acid (DOPAC) inhibits brain respiratory chain activity by autoxidation and mitochondria catalyzed oxidation to quinone products: implications in Parkinson's disease.
    Jana S; Maiti AK; Bagh MB; Banerjee K; Das A; Roy A; Chakrabarti S
    Brain Res; 2007 Mar; 1139():195-200. PubMed ID: 17291463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson's disease.
    Khan FH; Sen T; Maiti AK; Jana S; Chatterjee U; Chakrabarti S
    Biochim Biophys Acta; 2005 Jun; 1741(1-2):65-74. PubMed ID: 15925494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders.
    Payer DE; Guttman M; Kish SJ; Tong J; Strafella A; Zack M; Adams JR; Rusjan P; Houle S; Furukawa Y; Wilson AA; Boileau I
    Mov Disord; 2015 Feb; 30(2):160-6. PubMed ID: 25641350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic neurons reduced to silence by oxidative stress: an early step in the death cascade in Parkinson's disease?
    Michel PP; Ruberg M; Hirsch E
    Sci STKE; 2006 Apr; 2006(332):pe19. PubMed ID: 16639033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects.
    Kim HJ; Im JH; Yang SO; Moon DH; Ryu JS; Bong JK; Nam KP; Cheon JH; Lee MC; Lee HK
    J Nucl Med; 1997 Nov; 38(11):1703-11. PubMed ID: 9374337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Peek into Parkinson's Disease Progression through Human Dopamine Neurons in a Dish.
    Yang N; Yue Z
    Trends Neurosci; 2018 Feb; 41(2):74-76. PubMed ID: 29248177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of levodopa on corticostriatal circuits supporting working memory in Parkinson's disease.
    Simioni AC; Dagher A; Fellows LK
    Cortex; 2017 Aug; 93():193-205. PubMed ID: 28675834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.